Triana Biomedicines is a private biopharmaceutical company building a target-first, proximity-first discovery platform to design molecular glue degraders that induce or enhance the breakdown of disease-causing proteins. Powered by bespoke chemical libraries, high-resolution structural biology and deep mechanistic insights, the platform is aimed at cancer indications where current modalities fall short. Its lead candidate, TRI-611, selectively degrades anaplastic lymphoma kinase (ALK) variants and is being advanced toward clinical proof of concept in ALK-positive non-small cell lung cancer. The company plans to nominate a second clinical candidate in 2026 and to mature multiple additional programs from its pipeline. An oversubscribed $120 million Series B round has strengthened the balance sheet and is expected to fund TRI-611 through early clinical studies while expanding the broader portfolio. No revenue or patient data have been disclosed, reflecting the company’s preclinical stage. Headquarters and laboratory operations are located in Lexington, Massachusetts.

Total raised

$230M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2025